This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism

This study has been completed.
Ted Daley, President
Information provided by (Responsible Party):
Raptor Pharmaceuticals Inc. Identifier:
First received: April 16, 2008
Last updated: September 25, 2012
Last verified: November 2009
This trial will evaluate if fomepizole (4-methylpyrazole)can treat symptoms associated with alcohol intolerance due to aldehyde dehydrogenase 2 (ALDH2) Deficiency, an inherited metabolic disorder. These symptoms include flushing, nausea, headache, shortness of breath and dizziness, resulting from exposure to acetaldehyde, the primary metabolite of ethanol. Long-term, serious health risks have been associated with repeated exposure to acetaldehyde, a carcinogen, among ALDH2-deficient individuals.

Condition Intervention Phase
Acetaldehyde Toxicity ALDH2 Deficiency Altered Ethanol Metabolism Drug: fomepizole; Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Phase IIa, Prospective, Randomized, Blinded, Intra-Subject Controlled, Dose Escalation Study of Fomepizole for Mitigation of Acetaldehyde Related Toxicity in Human Subjects With Altered Ethanol Metabolism With Concomitant Ethanol Exposure

Resource links provided by NLM:

Further study details as provided by Raptor Pharmaceuticals Inc.:

Primary Outcome Measures:
  • Safety and tolerability of oral fomepizole with concomitant ethanol administration in subjects with symptoms of with symptoms of acetaldehyde toxicity associated with altered ethanol metabolism [ Time Frame: 1 week ]

Secondary Outcome Measures:
  • PK of 4-MP, ethanol and acetaldehyde in subjects with symptoms of acetaldehyde toxicity associated with altered ethanol metabolism following a single oral dose of fomepizole with concomitant ethanol administration [ Time Frame: 1 week ]

Enrollment: 32
Study Start Date: April 2008
Study Completion Date: July 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: fomepizole;
    Each subject will, in a blinded controlled manner, receive alternating study treatment (fomepizole or placebo) on 2 sequential days (Study Day 1 and Study Day 2). In addition, the study drug (fomepizole or placebo) will be administered in the 4 subjects in each cohort 30 minutes prior to ethanol, and in 4 subjects in each cohort 30 minutes after the ethanol.
    Other Names:
    • fomepizole
    • 4-MP
Detailed Description:
Approximately 32 subjects will be enrolled in ascending dosing cohorts of 8 subjects each. Each subject will receive an oral dose of study drug (fomepizole or placebo) with concomitant ethanol with group assignment in a randomized 1:1:1:1 ratio (2 subjects each group) on Study Day 1. Each subject is their own intra-subject control with the alternative study drug (fomepizole or placebo) administered on the next day (Study Day 2). Four subjects in each cohort will receive study drug (fomepizole or placebo) administered 30 minutes prior to ethanol, 4 with study drug (fomepizole or placebo) administered 30 minutes after ethanol. The study will assess safety and tolerability of fomepizole and the PK/PD of 4-MP, ethanol and acetaldehyde in the subject population.

Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Signed informed consent
  • Age 21 to 50 years
  • Subject of Japanese descent
  • History of flushing, with or without palpitations, or nausea (ALST ≥ 3.1) following occasional or inadvertent ethanol consumption either currently or in the past
  • Subjects must be healthy volunteers with no other clinically relevant abnormalities as determined by medical history, blood chemistry, complete blood count (CBC), urinalysis,and 12-lead electrocardiogram (ECG)
  • Positive skin ethanol patch test (100 μL of 70% ethanol on a lint pad applied to skin for 7 minutes results in an area of erythema)

Exclusion Criteria:

  • Vaccination within 2 weeks of Day 1
  • Current respiratory disease or a past history of chronic respiratory disease, or current smoker within last six months
  • Any one of the following Screening ECG findings:

    • QTc (Bazett) interval duration greater than 450 msec (male) or 470 msec (female), or
    • QRS interval greater than 120 msec, or
    • PR interval greater than 220 msec
  • History or evidence of drug or alcohol abuse or regular consumption of more than 8 units of alcohol daily (1 unit = 300 mL beer, 1 glass wine, 1 measure spirit) or those who may have difficulty abstaining from non study alcohol during the 36 hours prior to dose administration and until completion of blood sampling on Day 7
  • Subjects who have donated blood totalling more than 550 mL within the 3 months prior to Day 1
  • Use of any prescription medication other than oral contraceptives during the 14 days prior to Day 1, unless approved by both the Principal Investigator (PI) and the Sponsor
  • Inability to abstain from smoking any tobacco product from within prior to 2 hours of blood sampling to after 2 hours of blood sampling during the study period.
  • Use of any over-the-counter product, herbal product, diet aid, hormone supplement, etc., within 14 days prior to Day 1 unless approved by both the PI and the Sponsor
  • Chronic use of pain medications
  • Administration of an investigational agent within the last 30 days (or within a period of less than 5 times the agent's half-life, whichever is longer) prior to Day 1
  • Major surgery within 60 days prior to Day 1, or any planned surgery or medical procedure during the study period (through Day 7)
  • Positive alcohol breath-test or Positive drug screen (e.g., opiates, barbiturates, cannabinoids, benzodiazepines, cocaine, amphetamines) during screening or at Day 0 Check-In
  • Known hypersensitivity reaction to Antizol® or other pyrazoles, tomato juice
  • Abnormal laboratory results, including:

    • WBC ≤3.5 × 109/L or neutrophil count ≤2.0 × 109/L
    • Hemoglobin <12.0 or >16.0 gm/dL
    • Creatinine ≥2 mg/dL
    • Total bilirubin ≥2 mg/dL
    • Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥2 times the upper limit of normal (ULN)
    • PaO2 ≤95% on room air by pulse oximetry
    • Urine dipstick positive for protein, blood, ketones, glucose or leukocyte esterase
  • Any other clinically significant abnormal result for hematology, clinical chemistry, or urinalysis at screening or Check-In
  • Positive serum pregnancy test for females of childbearing potential
  • Subject and/or partner unable or unwilling to use an effective form of barrier contraceptives during the course of the study and for 7 days after study drug administration.
  • Cancer (excluding adequately treated basal cell carcinoma) within the last 5 years
  • Significant past medical history of hepatic, renal, cardiovascular (including family history of prolonged QT syndrome), pulmonary, gastrointestinal, hematological, locomotor, immunologic, ophthalmologic, metabolic endocrine or other diseases; or any condition that in the opinion of the Investigator would complicate or compromise the study, or the well-being of the subject
  • Any other reason, which in the opinion of the Principal Investigator, would prevent the subject from completing or following the study schedule
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00661141

United States, California
Covance Honolulu CRU
Honolulu, California, United States, 96813
Sponsors and Collaborators
Raptor Pharmaceuticals Inc.
Ted Daley, President
Principal Investigator: James Ruckle, MD Covanance Honolulu CRU